-

Shareholder Alert: Robbins LLP is Investigating Splunk, Inc. (SPLK) on Behalf of Shareholders

SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Splunk, Inc. (NASDAQ: SPLK) on behalf of shareholders to determine whether certain Splunk officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. Splunk develops and markets software solutions that enable organizations to gain real-time organizational intelligence in the U.S. and internationally.

If you suffered a loss due to Splunk Inc.'s misconduct, click here.

Splunk, Inc. (SPLK) Misled Shareholders About its Third Quarter 2021 Financial Results

On October 21, 2020, Splunk held a call with several analysts at the Virtual Analyst & Investor Session at .conf20. During the call, Splunk assured investors that everything was on track for its third quarter 2021 financial results. However, after the markets closed on December 2, 2020, Splunk announced disappointing results for its third quarter 2021, including an 11% decrease in total revenues, which missed estimates by nearly $60 million. On an earnings call the same day, Splunk admitted that despite reiterating its 2021 third quarter guidance just 10 days before the close of the quarter, the results fell "short of both our expectation and our communication of those expectations." On this news, JPMorgan announced it was "blindsided by the magnitude of too many large details slipping in the final days of October." Shares of Splunk plummeted, closing down over 24% on December 3, 2020. Shareholders later learned that Splunk had failed to disclose it was not closing deals with its largest customers and was not hitting the financial targets it had previously announced.

Splunk, Inc. (SPLK) Shareholders Have Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Splunk, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Did You Lose Money in Stride, Inc.? Contact Robbins LLP for Information About Your Rights Against LRN.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: The company: Stride, Inc. (NYSE: LRN) is a technology company that provides an education platform to deliver online learning to students throughout the U.S. What is the class period? October 22, 2024 - October 28, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Stride during the class period because the Company allegedly misled investors regarding i...

Did You Lose Money in Perrigo Company? PRGO Stockholders Should Contact Robbins LLP for Information About Their Rights Against PRGO.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Perrigo Company (NYSE: PRGO) provides over-the-counter health and wellness solutions in the U.S., Europe, and internationally. What is the class period? February 27, 2024 - November 4, 2025 What is the Case About? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who acquired Perrigo securities during the class period because the Company allegedly misled investors regarding the value of its infant formula...

Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Skye Bioscience, Inc. (NYSE: SKYE) is a clinical stage biopharmaceutical company that focuses on developing molecules that modulate G protein-coupled receptors (“GPCRs”) to treat obesity, overweight, and metabolic diseases. The Company’s lead product candidate is nimacimab. What is the class period? November 4, 2024 - October 3, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors...
Back to Newsroom